Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been growing swiftly worldwide. Patients with background chronic pulmonary inflammations such as asthma or chronic obstructive pulmonary diseases (COPD) are likely to be infected with this virus. Of note, there is an argument that COVID-19 can remain with serious complications like fibrosis or other pathological changes in the pulmonary tissue of patients with chronic diseases. Along with conventional medications, regenerative medicine, and cell-based therapy could be alternative approaches to compensate for organ loss or restore injured sites using different stem cell types. Owing to unique differentiation capacity and paracrine activity, these cells can accelerate the healing procedure. In this review article, we have tried to scrutinize different reports related to the harmful effects of SARS-CoV-2 on patients with asthma and COPD, as well as the possible therapeutic effects of stem cells in the alleviation of post-COVID-19 complications.

中文翻译：

---

患有慢性阻塞性肺病 (COPD) 和哮喘的康复后的 COVID-19 患者即将出现的并发症；可能的治疗机会

严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 感染在全球范围内迅速增长。患有哮喘或慢性阻塞性肺疾病（COPD）等慢性肺部炎症的患者很可能感染这种病毒。值得注意的是，有一种观点认为，慢性病患者的肺组织中，COVID-19 可能会留下严重的并发症，如纤维化或其他病理变化。除了传统药物之外，再生医学和细胞疗法可能是补偿器官损失或使用不同干细胞类型恢复受损部位的替代方法。由于独特的分化能力和旁分泌活性，这些细胞可以加速愈合过程。在这篇综述文章中，我们试图仔细审查有关 SARS-CoV-2 对哮喘和慢性阻塞性肺病患者的有害影响的不同报告，以及干细胞在缓解 COVID-19 后并发症方面的可能治疗效果。